Molecular confirmation of founder mutation c.-167A>G in Tunisian patients with PMLD disease

Gene. 2013 Jan 25;513(2):233-8. doi: 10.1016/j.gene.2012.10.070. Epub 2012 Nov 7.

Abstract

Pelizaeus Merzbacher disease and Pelizaeus Merzbacher like disease (PMLD) are hypomyelinating leucodystrophies of the central nervous system (CNS) with a very similar phenotype. PMD is an X-linked recessive condition caused by mutations, deletion duplication or triplication of the proteolipid protein 1 gene (PLP1). However, PMLD is a recessive autosomal hypomyelinating leukodystrophy caused by mutations of the GJC2 gene. In this study, we analyzed 5 patients belonging to 4 Tunisian families. Direct sequencing of GJC2 gene in all probands showed the same homozygous founder mutation c.-167A>G localized in the promoter region. We also generated two microsatellite markers GJC2 195GT and GJC2 76AC closed to the GJC2 gene to confirm the presence of a founder effect for this mutation. Haplotype study showed that the c.-167A>G promoter mutation occurred in a specific founder haplotype in Tunisian population. The identification of this founder mutation has important implications towards genetic counseling in relatives of these families and the antenatal diagnosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Connexins / genetics*
  • Female
  • Founder Effect*
  • Haplotypes / genetics
  • Humans
  • Male
  • Microsatellite Repeats
  • Mutation*
  • Pelizaeus-Merzbacher Disease / genetics*
  • Phorbols
  • Promoter Regions, Genetic
  • Tunisia

Substances

  • Connexins
  • Phorbols
  • connexin 47
  • pedilstatin